OCTN cation transporters in health and disease: Role as drug targets and assay development

Journal of Biomolecular Screening

Volumn 18, Issue 8, 2013, Pages 851-867

  Pochini, Lorena ^a   Scalise, Mariafrancesca ^a   Galluccio, Michele ^a   Indiveri, Cesare ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

acetylcholine; carnitine; drugs; OCTN; review; transporters

Indexed keywords

ACETYLCARNITINE; ADENOSINE TRIPHOSPHATE; CARNITINE; CARNITINE ACETYLTRANSFERASE; GAMMA BUTYROBETAINE; INSULIN; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEOLIPOSOME;

ALZHEIMER DISEASE; CARBOXY TERMINAL SEQUENCE; CARNITINE DEFICIENCY; CELL MEMBRANE; CHOLINERGIC SYSTEM; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG SCREENING; DRUG TARGETING; ENTERITIS; ENZYME SPECIFICITY; ENZYME SUBSTRATE COMPLEX; FATTY ACID METABOLISM; GENE MUTATION; HORMONAL REGULATION; HYDROGEN BOND; MITOCHONDRION; MOLECULAR INTERACTION; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURAL HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINE; CARNITINE; DRUGS; OCTN; REVIEW; TRANSPORTERS;

ACETYLCHOLINE; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; CARNITINE; HUMANS; INFLAMMATORY BOWEL DISEASES; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; ORGANIC CATION TRANSPORT PROTEINS; PROTEOLIPIDS;

EID: 84882294308     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057113493006     Document Type: Review

References (161)

1. Huang S. M., Strong J. M., Zhang L., et al. New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process. J. Clin. Pharmacol. 2008 ; 48: 662-670
2. Giacomini K. M., Huang S. M., Tweedie D. J., et al. Membrane Transporters in Drug Development. Nat. Rev. Drug. Discov. 2010 ; 9: 215-236
3. Han H. K.. Role of Transporters in Drug Interactions. Arch. Pharm. Res. 2011 ; 34: 1865-1877
4. Nakanishi T., Tamai I.. Solute Carrier Transporters as Targets for Drug Delivery and Pharmacological Intervention for Chemotherapy. J. Pharm. Sci. 2011 ; 100: 3731-3750
5. DeGorter M. K., Xia C. Q., Yang J. J., et al. Drug Transporters in Drug Efficacy and Toxicity. Annu. Rev. Pharmacol. Toxicol. 2012 ; 52: 249-273
6. Agarwal S., Chinn L., Zhang L.. An Overview of Transporter Information in Package Inserts of Recently Approved New Molecular Entities. Pharm. Res. 2012 ; 30: 899-910
7. Mandery K., Glaeser H., Fromm M. F.. Interaction of Innovative Small Molecule Drugs Used for Cancer Therapy with Drug Transporters. Br. J. Pharmacol. 2012 ; 165: 345-362
8. Lounkine E., Keiser M. J., Whitebread S., et al. Large-Scale Prediction and Testing of Drug Activity on Side-Effect Targets. Nature. 2012 ; 486: 361-367
9. Neuhoff S., Ungell A. L., Zamora I., et al. pH-Dependent Bidirectional Transport of Weakly Basic Drugs across Caco-2 Monolayers: Implications for Drug-Drug Interactions. Pharm. Res. 2003 ; 20: 1141-1148
10. Koepsell H.. The SLC22 Family with Transporters of Organic Cations, Anions and Zwitterions. Mol. Aspects Med. 2013 ; 34: 413-435
11. Ciarimboli G.. Role of Organic Cation Transporters in Drug-Induced Toxicity. Expert Opin. Drug. Metab. Toxicol. 2011 ; 7: 159-174
12. Eraly S. A., Monte J. C., Nigam S. K.. Novel slc22 Transporter Homologs in Fly, Worm, and Human Clarify the Phylogeny of Organic Anion and Cation Transporters. Physiol. Genomics. 2004 ; 18: 12-24
13. Saier M. H., Yen M. R., Noto K., et al. The Transporter Classification Database: Recent Advances. Nucleic Acids Res. 2009 ; 37: D274 - D278
14. Indiveri C., Galluccio M., Scalise M., et al. Strategies of Bacterial Over Expression of Membrane Transporters Relevant in Human Health: The Successful Case of the Three Members of OCTN Subfamily. Mol. Biotechnol. 2013 ; 54: 724-736
15. Pochini L., Oppedisano F., Indiveri C.. Reconstitution into Liposomes and Functional Characterization of the Carnitine Transporter from Renal Cell Plasma Membrane. Biochim. Biophys. Acta. 2004 ; 1661: 78-86
16. Pochini L., Scalise M., Galluccio M., et al. Reconstitution in Liposomes of the Functionally Active Human OCTN1 (SLC22A4) Transporter Overexpressed. Escherichia coli. Biochem. J. 2011 ; 439: 227-233
17. Scalise M., Galluccio M., Pochini L., et al. Over-expression in Escherichia coli, Purification and Reconstitution in Liposomes of the Third Member of the OCTN Sub-family: The Mouse Carnitine Transporter OCTN3. Biochem. Biophys. Res. Commun. 2012 ; 422: 59-63
18. Hopf T. A., Colwell L. J., Sheridan R.. Three-Dimensional Structures of Membrane Proteins from Genomic Sequencing. Cell. 2012 ; 149: 1607-1621
19. Forrest L. R., Kramer R., Ziegler C.. The Structural Basis of Secondary Active Transport Mechanisms. Biochim. Biophys. Acta. 2011 ; 1807: 167-188
20. Schulze S., Koster S., Geldmacher U., et al. Structural Basis of Na(+)-Independent and Cooperative Substrate/Product Antiport in CaiT. Nature. 2010 ; 467: 233-236
21. Tang L., Bai L., Wang W. H., et al. Crystal Structure of the Carnitine Transporter and Insights into the Antiport Mechanism. Nat. Struct. Mol. Biol. 2010 ; 17: 492-496
22. Pochini L., Scalise M., Indiveri C.. Inactivation by Omeprazole of the Carnitine Transporter (OCTN2) Reconstituted in Liposomes. Chem. Biol. Interact. 2009 ; 179: 394-401
23. Colucci W. J., Gandour R. D., Mooberry E. A.. Conformational Analysis of Charged Flexible Molecules in Water by Application of a New Karplus Equation Combined with MM2 Computations: Conformations of Carnitine and Acetylcarnitine. J. Am. Chem. Soc. 1986 ; 108: 7141-7147
24. Tamai I., Yabuuchi H., Nezu J., et al. Cloning and Characterization of a Novel Human pH-Dependent Organic Cation Transporter, OCTN1. FEBS Lett. 1997 ; 419: 107-111
25. Yabuuchi H., Tamai I., Nezu J., et al. Novel Membrane Transporter OCTN1 Mediates Multispecific, Bidirectional, and pH-Dependent Transport of Organic Cations. J. Pharmacol. Exp. Ther. 1999 ; 289: 768-773
26. Tamai I., Ohashi R., Nezu J. I., et al. Molecular and Functional Characterization of Organic Cation/Carnitine Transporter Family in Mice. J. Biol. Chem. 2000 ; 275: 40064-40072
27. Wu X., George R. L., Huang W., et al. Structural and Functional Characteristics and Tissue Distribution Pattern of Rat OCTN1, an Organic Cation Transporter, Cloned from Placenta. Biochim. Biophys. Acta. 2000 ; 1466: 315-327
28. Tamai I., Nakanishi T., Kobayashi D., et al. Involvement of OCTN1 (SLC22A4) in pH-Dependent Transport of Organic Cations. Mol. Pharm. 2004 ; 1: 57-66
29. Pochini L., Scalise M., Galluccio M., et al. The Human OCTN1 (SLC22A4) Reconstituted in Liposomes Catalyzes Acetylcholine Transport Which Is Defective in the Mutant L503F Associated to the Crohn's Disease. Biochim. Biophys. Acta. 2012 ; 1818: 559-565
30. Okabe M., Szakacs G., Reimers M. A., et al. Profiling SLCO and SLC22 Genes in the NCI-60 Cancer Cell Lines to Identify Drug Uptake Transporters. Mol. Cancer. Ther. 2008 ; 7: 3081-3091
31. Wright S. H., Dantzler W. H.. Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport. Physiol. Rev. 2004 ; 84: 987-1049
32. Horvath G., Schmid N., Fragoso M. A., et al. Epithelial Organic Cation Transporters Ensure pH-Dependent Drug Absorption in the Airway. Am. J. Respir. Cell. Mol. Biol. 2007 ; 36: 53-60
33. Garrett Q., Xu S., Simmons P. A., et al. Expression and Localization of Carnitine/Organic Cation Transporter OCTN1 and OCTN2 in Ocular Epithelium. Invest. Ophthalmol. Vis. Sci. 2008 ; 49: 4844-4849
34. Sugiura T., Kato S., Shimizu T., et al. Functional Expression of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Mouse Small Intestine and Liver. Drug. Metab. Dispos. 2010 ; 38: 1665-1672
35. Lamhonwah A. M., Tein I.. Novel Localization of OCTN1, an Organic Cation/Carnitine Transporter, to Mammalian Mitochondria. Biochem. Biophys. Res. Commun. 2006 ; 345: 1315-1325
36. Shitara Y., Nakamichi N., Norioka M., et al. Role of Organic Cation/Carnitine Transporter 1 in Uptake of Phenformin and Inhibitory Effect on Complex I Respiration in Mitochondria. Toxicol. Sci. 2013 ; 132: 32-42
37. Grundemann D., Harlfinger S., Golz S., et al. Discovery of the Ergothioneine Transporter. Proc. Natl. Acad. Sci. U. S. A. 2005 ; 102: 5256-5261
38. Kato Y., Kubo Y., Iwata D., et al. Gene Knockout and Metabolome Analysis of Carnitine/Organic Cation Transporter OCTN1. Pharm. Res. 2010 ; 27: 832-840
39. Nikodemus D., Lazic D., Bach M., et al. Paramount Levels of Ergothioneine Transporter SLC22A4 mRNA in Boar Seminal Vesicles and Cross-Species Analysis of Ergothioneine and Glutathione in Seminal Plasma. J. Physiol. Pharmacol. 2011 ; 62: 411-419
40. Pochini L., Scalise M., Galluccio M., et al. Regulation by Physiological Cations of Acetylcholine Transport Mediated by Human OCTN1 (SLC22A4): Implications in the Non-neuronal Cholinergic System. Life Sci. 2012 ; 91: 1013-1016
41. Peltekova V. D., Wintle R. F., Rubin L. A., et al. Functional Variants of OCTN Cation Transporter Genes Are Associated with Crohn Disease. Nat. Genet. 2004 ; 36: 471-475
42. Nakamura T., Yoshida K., Yabuuchi H., et al. Functional Characterization of Ergothioneine Transport by Rat Organic Cation/Carnitine Transporter Octn1 (slc22a4). Biol. Pharm. Bull. 2008 ; 31: 1580-1584
43. Indiveri C., Pochini L., Oppedisano F., et al. The Carnitine Transporter Network: Interactions with Drugs. Curr. Chem. Biol. 2010 ; 4: 108-123
44. Clark P. M., Dawany N., Dampier W., et al. Bioinformatics Analysis Reveals Transcriptome and MicroRNA Signatures and Drug Repositioning Targets for IBD and Other Autoimmune Diseases. Inflamm. Bowel. Dis. 2012 ; 18: 2315-2333
45. Sonne S., Shekhawat P. S., Matern D., et al. Carnitine Deficiency in OCTN2-/- Newborn Mice Leads to a Severe Gut and Immune Phenotype with Widespread Atrophy, Apoptosis and a Pro-inflammatory Response. PLoS One. 2012 ; 7: e47729
46. Fortin G., Yurchenko K., Collette C., et al. L-Carnitine, a Diet Component and Organic Cation Transporter OCTN Ligand, Displays Immunosuppressive Properties and Abrogates Intestinal Inflammation. Clin. Exp. Immunol. 2009 ; 156: 161-171
47. Tein I., Bukovac S. W., Xie Z. W.. Characterization of the Human Plasmalemmal Carnitine Transporter in Cultured Skin Fibroblasts. Arch. Biochem. Biophys. 1996 ; 329: 145-155
48. Arduini A., Bonomini M., Savica V., et al. Carnitine in Metabolic Disease: Potential for Pharmacological Intervention. Pharmacol. Ther. 2008 ; 120: 149-156
49. Samuel V. T., Shulman G. I.. Mechanisms for Insulin Resistance: Common Threads and Missing Links. Cell. 2012 ; 148: 852-871
50. Ringseis R., Keller J., Eder K.. Role of Carnitine in the Regulation of Glucose Homeostasis and Insulin Sensitivity: Evidence from In Vivo and In Vitro Studies with Carnitine Supplementation and Carnitine Deficiency. Eur. J. Nutr. 2012 ; 51: 1-18
51. Martini M., Ferrara A. M., Giachelia M., et al. Association of the OCTN1/1672T Variant with Increased Risk for Colorectal Cancer in Young Individuals and Ulcerative Colitis Patients. Inflamm. Bowel Dis. 2012 ; 18: 439-448
52. Minchinton A. I., Tannock I. F.. Drug Penetration in Solid Tumours. Nat. Rev. Cancer. 2006 ; 6: 583-592
53. Owen L., Sunram-Lea S. I.. Metabolic Agents That Enhance ATP Can Improve Cognitive Functioning: A Review of the Evidence for Glucose, Oxygen, Pyruvate, Creatine, and L-Carnitine. Nutrients. 2011 ; 3: 735-755
54. Lin M. T., Beal M. F.. Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases. Nature. 2006 ; 443: 787-795
55. Jones L. L., McDonald D. A., Borum P. R.. Acylcarnitines: Role in Brain. Prog. Lipid Res. 2010 ; 49: 61-75
56. Kido Y., Tamai I., Ohnari A., et al. Functional Relevance of Carnitine Transporter OCTN2 to Brain Distribution of L-Carnitine and Acetyl-L-Carnitine across the Blood-Brain Barrier. J. Neurochem. 2001 ; 79: 959-969
57. Rossignol D. A., Frye R. E.. Mitochondrial Dysfunction in Autism Spectrum Disorders: A Systematic Review and Meta-analysis. Mol. Psychiatry. 2012 ; 17: 290-314
58. Cuturic M., Abramson R. K., Moran R. R., et al. Serum Carnitine Levels and Levocarnitine Supplementation in Institutionalized Huntington's Disease Patients. Neurol. Sci. 2013 ; 34: 93-98
59. Jong N. N., Nakanishi T., Liu J. J., et al. Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons. J. Pharmacol. Exp. Ther. 2011 ; 338: 537-547
60. Tamai I., Ohashi R., Nezu J., et al. Molecular and Functional Identification of Sodium Ion-Dependent, High Affinity Human Carnitine Transporter OCTN2. J. Biol. Chem. 1998 ; 273: 20378-20382
61. Wagner C. A., Lukewille U., Kaltenbach S.;, et al. Functional and Pharmacological Characterization of Human Na(+)-Carnitine Cotransporter hOCTN2. Am. J. Physiol. Renal Physiol. 2000 ; 279: F584 - F591
62. Xuan W., Lamhonwah A. M., Librach C., et al. Characterization of Organic Cation/Carnitine Transporter Family in Human Sperm. Biochem. Biophys Res. Commun. 2003 ; 306: 121-128
63. Yakushiji K., Kai S., Yamauchi M., et al. Expression and Distribution of OCTN2 in Mouse Epididymis and Its Association with Obstructive Azoospermia in Juvenile Visceral Steatosis Mice. Int. J. Urol. 2006 ; 13: 420-426
64. Ohashi R., Tamai I., Yabuuchi H., et al. Na(+)-Dependent Carnitine Transport by Organic Cation Transporter (OCTN2): Its Pharmacological and Toxicological Relevance. J. Pharmacol. Exp. Ther. 1999 ; 291: 778-784
65. Ohashi R., Tamai I., Nezu J., et al. Molecular and Physiological Evidence for Multifunctionality of Carnitine/Organic Cation Transporter OCTN2. Mol. Pharmacol. 2001 ; 59: 358-366
66. Ohashi R., Tamai I., Inano A., et al. Studies on Functional Sites of Organic Cation/Carnitine Transporter OCTN2 (SLC22A5) Using a Ser467Cys Mutant Protein. J. Pharmacol. Exp. Ther. 2002 ; 302: 1286-1294
67. Todesco L., Bur D., Brooks H., et al. Pharmacological Manipulation of L-Carnitine Transport into L6 Cells with Stable Overexpression of Human OCTN2. Cell. Mol. Life Sci. 2008 ; 65: 1596-1608
68. Scalise M., Galluccio M., Accardi R., et al. Human OCTN2 (SLC22A5) is Down-Regulated in Virus- and Nonvirus-Mediated Cancer. Cell. Biochem. Funct. 2012 ; 30: 419-425
69. Magoulas P. L., El-Hattab A. W.. Systemic Primary Carnitine Deficiency: An Overview of Clinical Manifestations, Diagnosis, and Management. Orphanet. J. Rare Dis. 2012 ; 7: 68
70. Rose E. C., di San Filippo C. A., Ndukwe Erlingsson U. C.;, et al. Genotype-Phenotype Correlation in Primary Carnitine Deficiency. Hum. Mutat. 2012 ; 33: 118-123
71. Chiechio S., Copani A., De Petris L., et al. Transcriptional Regulation of Metabotropic Glutamate Receptor 2/3 Expression by the NF-kappaB Pathway in Primary Dorsal Root Ganglia Neurons: A Possible Mechanism for the Analgesic Effect of L-Acetylcarnitine. Mol. Pain. 2006 ; 2: 20
72. Traina G., Federighi G., Brunelli M., et al. Cytoprotective Effect of Acetyl-L-Carnitine Evidenced by Analysis of Gene Expression in the Rat Brain. Mol. Neurobiol. 2009 ; 39: 101-106
73. Sandor A., Pecsuvac K., Kerner J., et al. On Carnitine Content of the Human Breast Milk. Pediatr. Res. 1982 ; 16: 89-91
74. Tein I., De Vivo D. C., Bierman F., et al. Impaired Skin Fibroblast Carnitine Uptake in Primary Systemic Carnitine Deficiency Manifested by Childhood Carnitine-Responsive Cardiomyopathy. Pediatr. Res. 1990 ; 28: 247-255
75. Ganapathy M. E., Huang W., Rajan D. P., et al. Beta-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/Carnitine Transporter. J. Biol. Chem. 2000 ; 275: 1699-1707
76. Diao L., Ekins S., Polli J. E.. Quantitative Structure Activity Relationship for Inhibition of Human Organic Cation/Carnitine Transporter. Mol. Pharm. 2010 ; 7: 2120-2131
77. Kobayashi D., Tamai I., Sai Y., et al. Transport of Carnitine and Acetylcarnitine by Carnitine/Organic Cation Transporter (OCTN) 2 and OCTN3 into Epididymal Spermatozoa. Reproduction. 2007 ; 134: 651-658
78. Cano M. M., Calonge M. L., Ilundain A. A.. Expression of OCTN2 and OCTN3 in the Apical Membrane of Rat Renal Cortex and Medulla. J. Cell. Physiol. 2010 ; 223: 451-459
79. Januszewicz E., Bekisz M., Mozrzymas J. W., et al. High Affinity Carnitine Transporters from OCTN Family in Neural Cells. Neurochem. Res. 2010 ; 35: 743-748
80. Lamhonwah A. M., Mai L., Chung C., et al. Upregulation of Mammary Gland OCTNs Maintains Carnitine Homeostasis in Suckling Infants. Biochem. Biophys. Res. Commun. 2011 ; 404: 1010-1015
81. Duran J. M., Peral M. J., Calonge M. L., et al. OCTN3: A Na+-Independent L-Carnitine Transporter in Enterocytes Basolateral Membrane. J. Cell. Physiol. 2005 ; 202: 929-935
82. Januszewicz E., Pajak B., Gajkowska B., et al. Organic Cation/Carnitine Transporter OCTN3 Is Present in Astrocytes and Is Up-regulated by Peroxisome Proliferators-Activator Receptor Agonist. Int. J. Biochem. Cell. Biol. 2009 ; 41: 2599-2609
83. Enomoto A., Wempe M. F., Tsuchida H., et al. Molecular Identification of a Novel Carnitine Transporter Specific to Human Testis: Insights into the Mechanism of Carnitine Recognition. J. Biol. Chem. 2002 ; 277: 36262-36271
84. Kummer W., Lips K. S., Pfeil U.. The Epithelial Cholinergic System of the Airways. Histochem. Cell. Biol. 2008 ; 130: 219-234
85. Wessler I., Kirkpatrick C. J.. Acetylcholine beyond Neurons: The Non-neuronal Cholinergic System in Humans. Br. J. Pharmacol. 2008 ; 154: 1558-1571
86. Wang H., Yu M., Ochani M., et al. Nicotinic Acetylcholine Receptor Alpha7 Subunit Is an Essential Regulator of Inflammation. Nature. 2003 ; 421: 384-388
87. Lamhonwah A. M., Wong J., Tam C., et al. Organic Cation/Carnitine Transporter Family Expression Patterns in Adult Murine Heart. Pathol. Res. Pract. 2009 ; 205: 395-402
88. Meetam P., Srimaroeng C., Soodvilai S., et al. Role of Estrogen in Renal Handling of Organic Cation, Tetraethylammonium: In Vivo and In Vitro Studies. Biol. Pharm. Bull. 2009 ; 32: 1968-1972
89. Meetam P., Srimaroeng C., Soodvilai S., et al. Regulatory Role of Testosterone in Organic Cation Transport: In Vivo and In Vitro Studies. Biol. Pharm. Bull. 2009 ; 32: 982-987
90. Lahjouji K., Malo C., Mitchell G. A., et al. L-Carnitine Transport in Mouse Renal and Intestinal Brush-Border and Basolateral Membrane Vesicles. Biochim. Biophys. Acta. 2002 ; 1558: 82-93
91. Ohnishi S., Saito H., Fukada A., et al. Distinct Transport Activity of Tetraethylammonium from L-Carnitine in Rat Renal Brush-Border Membranes. Biochim. Biophys. Acta. 2003 ; 1609: 218-224
92. Grube M., Meyer zu, Schwabedissen H. E., Prager D., et al. Uptake of Cardiovascular Drugs into the Human Heart: Expression, Regulation, and Function of the Carnitine Transporter OCTN2 (SLC22A5). Circulation. 2006 ; 113: 1114-1122
93. Ohnishi S., Okamura N., Sakamoto S., et al. Role of Na+/L-Carnitine Transporter (OCTN2) in Renal Handling of Pivaloylcarnitine and Valproylcarnitine Formed during Pivalic Acid-Containing Prodrugs and Valproic Acid Treatment. Drug. Metab. Pharmacokinet. 2008 ; 23: 293-303
94. Grigat S., Fork C., Bach M., et al. The Carnitine Transporter SLC22A5 Is Not a General Drug Transporter, But It Efficiently Translocates Mildronate. Drug. Metab. Dispos. 2009 ; 37: 330-337
95. Kano T., Kato Y., Ito K., et al. Carnitine/Organic Cation Transporter OCTN2 (Slc22a5) Is Responsible for Renal Secretion of Cephaloridine in Mice. Drug. Metab. Dispos. 2009 ; 37: 1009-1016
96. Maekawa S., Mori D., Nishiya T., et al. OCTN2VT, a Splice Variant of OCTN2, Does Not Transport Carnitine Because of the Retention in the Endoplasmic Reticulum Caused by Insertion of 24 Amino Acids in the First Extracellular Loop of OCTN2. Biochim. Biophys. Acta. 2007 ; 1773: 1000-1006
97. Kato Y., Sai Y., Yoshida K., et al. PDZK1 Directly Regulates the Function of Organic Cation/Carnitine Transporter OCTN2. Mol. Pharmacol. 2005 ; 67: 734-743
98. Nagai K., Takikawa O., Kawakami N., et al. Cloning and Functional Characterization of a Novel Up-regulator, Cartregulin, of Carnitine Transporter, OCTN2. Arch. Biochem. Biophys. 2006 ; 452: 29-37
99. Maeda T., Wakasawa T., Funabashi M., et al. Regulation of Octn2 Transporter (SLC22A5) by Peroxisome Proliferator Activated Receptor Alpha. Biol. Pharm. Bull. 2008 ; 31: 1230-1236
100. Stephens F. B., Constantin-Teodosiu D., Laithwaite D., et al. Insulin Stimulates L-Carnitine Accumulation in Human Skeletal Muscle. FASEB J. 2006 ; 20: 377-379
101. Fujiya M., Inaba Y., Musch M. W., et al. Cytokine Regulation of OCTN2 Expression and Activity in Small and Large Intestine. Inflamm. Bowel. Dis. 2011 ; 17: 907-916
102. Wang C., Uray I. P., Mazumdar A., et al. SLC22A5/OCTN2 Expression in Breast Cancer Is Induced by Estrogen via a Novel Intronic Estrogen-Response Element (ERE). Breast Cancer. Res. Treat. 2012 ; 134: 101-115
103. Lamhonwah A. M., Skaug J., Scherer S. W., et al. A Third Human Carnitine/Organic Cation Transporter (OCTN3) as a Candidate for the 5q31 Crohn's Disease Locus (IBD5). Biochem. Biophys. Res. Commun. 2003 ; 301: 98-101
104. Lamhonwah A. M., Hawkins C. E., Tam C., et al. Expression Patterns of the Organic Cation/Carnitine Transporter Family in Adult Murine Brain. Brain. Dev. 2008 ; 30: 31-42
105. Lamhonwah A. M., Ackerley C. A., Tilups A., et al. OCTN3 Is a Mammalian Peroxisomal Membrane Carnitine Transporter. Biochem. Biophys. Res. Commun. 2005 ; 338: 1966-1972
106. Newman B., Siminovitch K. A.. Recent Advances in the Genetics of Inflammatory Bowel Disease. Curr. Opin. Gastroenterol. 2005 ; 21: 401-407
107. Nalecz K. A., Miecz D., Berezowski V., et al. Carnitine: Transport and Physiological Functions in the Brain. Mol. Aspects. Med. 2004 ; 25: 551-567
108. Peluso G., Petillo O., Margarucci S., et al. Decreased Mitochondrial Carnitine Translocase in Skeletal Muscles Impairs Utilization of Fatty Acids in Insulin-Resistant Patients. Front. Biosci. 2002 ; 7: a109 - a116
109. Peluso G., Nicolai R., Reda E., et al. Cancer and Anticancer Therapy-Induced Modifications on Metabolism Mediated by Carnitine System. J. Cell. Physiol. 2000 ; 182: 339-350
110. Liang W. C., Nishino I.. State of the Art in Muscle Lipid Diseases. Acta Myol. 2010 ; 29: 351-356
111. Brass E. P., Mayer M. D., Mulford D. J., et al. Impact on Carnitine Homeostasis of Short-term Treatment with the Pivalate Prodrug Cefditoren Pivoxil. Clin. Pharmacol. Ther. 2003 ; 73: 338-347
112. Barile M., Giancaspero T. A., Brizio C., et al. Biosynthesis of Flavin Cofactors in Man: Implications in Health and Disease. Curr. Pharm. Des. 2013 ; 19: 2649-2675
113. Stanley C. A., Hale D. E., Berry G. T., et al. Brief Report: A Deficiency of Carnitine-Acylcarnitine Translocase in the Inner Mitochondrial Membrane. N. Engl. J. Med. 1992 ; 327: 19-23
114. Pande S. V., Brivet M., Slama A., et al. Carnitine-Acylcarnitine Translocase Deficiency with Severe Hypoglycemia and Auriculo Ventricular Block: Translocase Assay in Permeabilized Fibroblasts. J. Clin. Invest. 1993 ; 91: 1247-1252
115. Indiveri C., Iacobazzi V., Tonazzi A., et al. The Mitochondrial Carnitine/Acylcarnitine Carrier: Function, Structure and Physiopathology. Mol. Aspects Med. 2011 ; 32: 223-233
116. Melegh B., Bene J., Mogyorosy G., et al. Phenotypic Manifestations of the OCTN2 V295X Mutation: Sudden Infant Death and Carnitine-Responsive Cardiomyopathy in Roma Families. Am J. Med. Genet. A. 2004 ; 131: 121-126
117. Aouida M., Poulin R., Ramotar D.. The Human Carnitine Transporter SLC22A16 Mediates High Affinity Uptake of the Anticancer Polyamine Analogue Bleomycin-A5. J. Biol. Chem. 2010 ; 285: 6275-6284
118. Baumgart D. C., Carding S. R.. Inflammatory Bowel Disease: Cause and Immunobiology. Lancet. 2007 ; 369: 1627-1640
119. Boirivant M., Cossu A.. Inflammatory Bowel Disease. Oral Dis. 2012 ; 18: 1-15
120. Nicholson J. K., Holmes E., Kinross J., et al. Host-Gut Microbiota Metabolic Interactions. Science. 2012 ; 336: 1262-1267
121. Hooper L. V., Littman D. R., Macpherson A. J.. Interactions between the Microbiota and the Immune System. Science. 2012 ; 336: 1268-1273
122. Maynard C. L., Elson C. O., Hatton R. D., et al. Reciprocal Interactions of the Intestinal Microbiota and Immune System. Nature. 2012 ; 489: 231-241
123. Kjer-Nielsen L., Patel O., Corbett A. J., et al. MR1 Presents Microbial Vitamin B Metabolites to MAIT Cells. Nature. 2012 ; 491: 717-723
124. Rodriguez-Reyna T. S., Martinez-Reyes C., Yamamoto-Furusho J. K.. Rheumatic Manifestations of Inflammatory Bowel Disease. World J. Gastroenterol. 2009 ; 15: 5517-5524
125. Rebouche C. J., Seim H.. Carnitine Metabolism and Its Regulation in Microorganisms and Mammals. Annu. Rev. Nutr. 1998 ; 18: 39-61
126. Stenmark P., Gurmu D., Nordlund P.. Crystal Structure of CaiB, a Type-III CoA Transferase in Carnitine Metabolism. Biochemistry. 2004 ; 43: 13996-14003
127. Vaz F. M., Wanders R. J.. Carnitine Biosynthesis in Mammals. Biochem. J. 2002 ; 361: 417-429
128. Rebouche C. J.. Kinetics, Pharmacokinetics, and Regulation of L-Carnitine and Acetyl-L-Carnitine Metabolism. Ann. N. Y. Acad. Sci. 2004 ; 1033: 30-41
129. Muoio D. M., Noland R. C., Kovalik J. P., et al. Muscle-Specific Deletion of Carnitine Acetyltransferase Compromises Glucose Tolerance and Metabolic Flexibility. Cell. Metab. 2012 ; 15: 764-777
130. Ganapathy V., Thangaraju M., Prasad P. D.. Nutrient Transporters in Cancer: Relevance to Warburg Hypothesis and Beyond. Pharmacol. Ther. 2009 ; 121: 29-40
131. Raz N., Lindenberger U., Rodrigue K. M., et al. Regional Brain Changes in Aging Healthy Adults: General Trends, Individual Differences and Modifiers. Cereb. Cortex. 2005 ; 15: 1676-1689
132. Frank B., Gupta S.. A Review of Antioxidants and Alzheimer's Disease. Ann. Clin. Psychiatry. 2005 ; 17: 269-286
133. Forloni G., Angeretti N., Smiroldo S.. Neuroprotective Activity of Acetyl-L-Carnitine: Studies In Vitro. J. Neurosci. Res. 1994 ; 37: 92-96
134. Kobayashi D., Irokawa M., Maeda T.;, et al. Carnitine/Organic Cation Transporter OCTN2-Mediated Transport of Carnitine in Primary-Cultured Epididymal Epithelial Cells. Reproduction. 2005 ; 130: 931-937
135. Oppedisano F., Galluccio M., Indiveri C.. Inactivation by Hg2+ and Methylmercury of the Glutamine/Amino Acid Transporter (ASCT2) Reconstituted in Liposomes: Prediction of the Involvement of a CXXC Motif by Homology Modelling. Biochem. Pharmacol. 2010 ; 8: 1266-1273
136. Oppedisano F., Pochini L., Galluccio M., et al. The Glutamine/Amino Acid Transporter (ASCT2) Reconstituted in Liposomes: Transport Mechanism, Regulation by ATP and Characterization of the Glutamine/Glutamate Antiport. Biochim. Biophys. Acta. 2007 ; 1768: 291-298
137. Pochini L., Peta V., Indiveri C.. Inhibition of the OCTN2 Carnitine Transporter by HgCl(2) and Methylmercury in the Proteoliposome Experimental Model: Insights in the Mechanism of Toxicity. Toxicol. Mech. Methods. 2012 ; 23: 68-76
138. Quick M., Wright E. M.. Employing Escherichia coli to Functionally Express, Purify, and Characterize a Human Transporter. Proc. Natl. Acad. Sci. U. S. A. 2002 ; 99: 8597-8601
139. Keller T., Schwarz D., Bernhard F., et al. Cell Free Expression and Functional Reconstitution of Eukaryotic Drug Transporters. Biochemistry. 2008 ; 47: 4552-4564
140. Komatsu T., Hiasa M., Miyaji T., et al. Characterization of the Human MATE2 Proton-Coupled Polyspecific Organic Cation Exporter. Int. J. Biochem. Cell. Biol. 2011 ; 43: 913-918
141. Kramer R., Heberger H.. Functional Reconstitution of Carrier Proteins by Removal of Detergent with a Hydrophobic Ion Exchange Column. Biochim. Biophys. Acta. 1986 ; 863: 289-296
142. Coskun U., Grzybek M., Drechsel D., et al. Regulation of Human EGF Receptor by Lipids. Proc. Natl. Acad. Sci. U. S. A. 2011 ; 108: 9044-9048
143. Indiveri C., Palmieri L., Palmieri F.. Kinetic Characterization of the Reconstituted Ornithine Carrier from Rat Liver Mitochondria. Biochim. Biophys. Acta. 1994 ; 1188: 293-301
144. Watanabe K., Sawano T., Endo T.;, et al. Studies on Intestinal Absorption of Sulpiride (2): Transepithelial Transport of Sulpiride across the Human Intestinal Cell Line Caco-2. Biol. Pharm. Bull. 2002 ; 25: 1345-1350
145. Hu S., Franke R. M., Filipski K. K., et al. Interaction of Imatinib with Human Organic Ion Carriers. Clin. Cancer. Res. 2008 ; 14: 3141-3148
146. Georges B., Galland S., Rigault C.;, et al. Beneficial Effects of L-Carnitine in Myoblastic C2C12 Cells: Interaction with Zidovudine. Biochem. Pharmacol. 2003 ; 65: 1483-1488
147. Hirano T., Yasuda S., Osaka Y., et al. Mechanism of the Inhibitory Effect of Zwitterionic Drugs (Levofloxacin and Grepafloxacin) on Carnitine Transporter (OCTN2) in Caco-2 Cells. Biochim. Biophys. Acta. 2006 ; 1758: 1743-1750
148. Hu C., Lancaster C. S., Zuo Z.;, et al. Inhibition of OCTN2-Mediated Transport of Carnitine by Etoposide. Mol. Cancer Ther. 2012 ; 11: 921-929
149. Urban T. J., Brown C., Castro R. A.;, et al. Effects of Genetic Variation in the Novel Organic Cation Transporter, OCTN1, on the Renal Clearance of Gabapentin. Clin. Pharmacol. Ther. 2008 ; 83: 416-421
150. Nakamura T., Nakanishi T., Haruta T., et al. Transport of Ipratropium, an Anti-Chronic Obstructive Pulmonary Disease Drug, is Mediated by Organic Cation/Carnitine Transporters in Human Bronchial Epithelial Cells: Implications for Carrier-Mediated Pulmonary Absorption. Mol. Pharm. 2010 ; 7: 187-195
151. Piermatti O., Fringuelli F., Pochini L., et al. Synthesis and Characterization of Carnitine Nitro-Derivatives. Bioorg. Med. Chem. 2008 ; 16: 1444-1451
152. Oppedisano F., Catto M., Koutentis P. A., et al. Inactivation of the Glutamine/Amino Acid Transporter ASCT2 by 1,2,3-Dithiazoles: Proteoliposomes as a Tool to Gain Insights in the Molecular Mechanism of Action and of Antitumor Activity. Toxicol. Appl. Pharmacol. 2012 ; 265: 93-102
153. Wu X., Huang W., Prasad P. D., et al. Functional Characteristics and Tissue Distribution Pattern of Organic Cation Transporter 2 (OCTN2), an Organic Cation/Carnitine Transporter. J. Pharmacol. Exp. Ther. 1999 ; 290: 1482-1492
154. Palacin M., Estevez R., Bertran J., et al. Molecular Biology of Mammalian Plasma Membrane Amino Acid Transporters. Physiol. Rev. 1998 ; 78: 969-1054
155. Bode B. P.. Recent Molecular Advances in Mammalian Glutamine Transport. J. Nutr. 2001 ; 131: 2475S - 2485S
156. Broer S.. Adaptation of Plasma Membrane Amino Acid Transport Mechanisms to Physiological Demands. Pflugers Arch. 2002 ; 444: 457-466
157. Mackenzie B., Erickson J. D.. Sodium-Coupled Neutral Amino Acid (System N/A) Transporters of the SLC38 Gene Family. Pflugers Arch. 2004 ; 447: 784-795
158. Kanai Y., Hediger M. A.. The Glutamate/Neutral Amino Acid Transporter Family SLC1: Molecular, Physiological and Pharmacological Aspects. Pflugers Arch. 2004 ; 447: 469-479
159. Verrey F., Ristic Z., Romeo E., et al. Novel Renal Amino Acid Transporters. Annu. Rev. Physiol. 2005 ; 67: 557-572
160. McGivan J. D., Bungard C. I.. The Transport of Glutamine into Mammalian Cells. Front. Biosci. 2007 ; 12: 874-882
161. Broer S.. Amino Acid Transport across Mammalian Intestinal and Renal Epithelia. Physiol. Rev. 2008 ; 88: 249-286